Zheng Wan, Yongle Li. The Status of Warfarin in the Era of Novel Oral Anticoagulants[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003
Citation: Zheng Wan, Yongle Li. The Status of Warfarin in the Era of Novel Oral Anticoagulants[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 108-111. doi: 10.3969/j.issn.1674-9081.2018.02.003

The Status of Warfarin in the Era of Novel Oral Anticoagulants

doi: 10.3969/j.issn.1674-9081.2018.02.003
More Information
  • Corresponding author: WAN Zheng   Tel; 022- 60362426, E-mail: wanzhhh@vip.126.com
  • Received Date: 2017-12-29
  • Publish Date: 2018-03-30
  • Anticoagulation therapy is an important measure for the treatment and prevention of thromboembolic diseases, especially pulmonary embolism. Warfarin, as a classic anticoagulant drug, has been applied to thromboembolic diseases since the 1950s. Compared with warfarin, novel oral anticoagulants(NOACs) have the advantages of stable pharmacokinetics, fixed-dose usage, no need for frequent monitoring of coagulation function, less interaction with drugs and foods, and good drug safety. The emergence of NOACs has given clinicians more choice of drugs, and it also challenges warfarin's position in the field of anticoagulation. However, there is no medicine to replace warfarin yet in many clinical scenarios. Warfarin still has the value of its existence.
  • loading
  • [1] van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis[J]. JAMA, 2002, 288:2441-2448. doi:  10.1001/jama.288.19.2441
    [2] ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J]. Lancet, 2006, 367:1903-1912. doi:  10.1016/S0140-6736(06)68845-4
    [3] Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy toprevent stroke in patients who have nonvalvular atrial fibrillation [J]. Ann Intern Med, 2007, 146:857-867. doi:  10.7326/0003-4819-146-12-200706190-00007
    [4] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009, 361:1139-1151. doi:  10.1056/NEJMoa0905561
    [5] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med, 2011, 365:883-891. doi:  10.1056/NEJMoa1009638
    [6] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2011, 365:981-992. doi:  10.1056/NEJMoa1107039
    [7] Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2013, 369: 2093-2104. doi:  10.1056/NEJMoa1310907
    [8] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials [J]. Lancet, 2014, 383:955-962. doi:  10.1016/S0140-6736(13)62343-0
    [9] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Europace, 2016, 18:1609-1678. doi:  10.1093/europace/euw295
    [10] Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis [J].Circulation, 2014, 129: 764-772. doi:  10.1161/CIRCULATIONAHA.113.004450
    [11] Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism [J]. N Engl J Med, 2013, 369:1406-1415. doi:  10.1056/NEJMoa1306638
    [12] Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism [J]. N Engl J Med, 2013, 369: 799-808. doi:  10.1056/NEJMoa1302507
    [13] Investigators EP, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism [J]. N Engl J Med, 2012, 366:1287-1297. doi:  10.1056/NEJMoa1113572
    [14] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report [J]. Chest, 2016, 149:315-352. doi:  10.1016/j.chest.2015.11.026
    [15] Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabiga-tran versus warfarin in patients with mechanical heart valves [J].N Engl J Med, 2013, 369:1206-1214. doi:  10.1056/NEJMoa1300615
    [16] Hoffman R, Brenner B. The promise of novel direct oral anticoagulants[J]. Best Pract Res Clin Haematol, 2012, 25:351-360. doi:  10.1016/j.beha.2012.06.004
    [17] 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会.华法林抗凝治疗的中国专家共识[J].中华内科杂志, 2013:76-82. doi:  10.3760/cma.j.issn.0578-1426.2013.01.027
    [18] Gallagher AM, Setakis E, Plumb JM, et al. Risks of strokeand mortality associated with suboptimal anticoagulation in atrial fibrillation patients [J]. Thromb Haemost, 2011, 106: 968-977. doi:  10.1160/TH11-05-0353
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (286) PDF downloads(400) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return